vimarsana.com
Home
Live Updates
Adagio Therapeutics, Inc.: Adagio Therapeutics Announces ADG
Adagio Therapeutics, Inc.: Adagio Therapeutics Announces ADG
Adagio Therapeutics, Inc.: Adagio Therapeutics Announces ADG20 (adintrevimab) is the First Monoclonal Antibody to Meet Primary Endpoints with Statistical Significance Across Pre- and Post-exposure Prophylaxis and Treatment for COVID-19 and Plans to Seek U
Risk of symptomatic COVID-19 was reduced by 71% compared to placebo in pre-exposure prophylaxis and 75% compared to placebo in post-exposure prophylaxis Risk of hospitalization or death in participants
Related Keywords
,
Ellie Hershberger ,
Dan Budwick ,
Monique Allaire ,
David Hering ,
Additional Development ,
Adagio Therapeutics Inc ,
Drug Administration ,
Division Of Organ Transplantation ,
Division Of Infectious Diseases ,
Nasdaq ,
Northwestern University Feinberg School Of Medicine ,
Exchange Commission ,
Strategic Communications ,
Research Updates ,
Emergency Use Authorization ,
Infectious Diseases ,
Organ Transplantation ,
Northwestern University Feinberg School ,
Fourth Quarter ,
Financial Guidance ,
Private Securities Litigation Reform Act ,
Convertible Preferred Stock ,
Stockholder Equity ,
Adagio ,
Herapeutics ,
Nnounces ,
Dg20 ,
Dintrevimab ,
First ,
Monoclonal ,
Ntibody ,
Feet ,
Primary ,
Endpoints ,
Tatistical ,
Significance ,
Cross ,
Most ,
Exposure ,
Prophylaxis ,
Treatment ,
Covid ,
Plans ,
The ,